TMO completed the acquisition of Brammer Bio, a leader in viral vector manufacturing for gene and cell therapies, for ~$1.7bn in cash. Brammer will become part of TMO’s Pharma Services business within its Laboratory Products and Services Segment. This acquisition will boost growth for the company and therefore, we expect 4% growth in revenues in […]
